The HAVEN study —hydroxychloroquine in ANCA vasculitis evaluation—a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan
DiscussionThis trial aims to explore Hydroxychloroquine as a treatment for patients with AAV. If effective, the need for immunosuppressive treatments such as prednisolone could be reduced. Hydroxychloroquine is safer, cheaper and has fewer adverse effects than conventional immunosuppressive treatments. This could improve patient outcomes while saving money for the NHS.Trial registrationISRCTN: ISRCTN79334891. Registered 07 June 2021.EudraCT: 2018-001268-40. Registered 13 September 2019.Clinicaltrials.gov: NCT04316494. Registered 20 March 2020. (Source: Trials)
Source: Trials - April 6, 2023 Category: Research Source Type: clinical trials
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
TARRYTOWN, N.Y., and SOUTH SAN FRANCISCO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sonoma Biotherapeutics, Inc. today announced a collaboration to apply their scientific and clinical expertise and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
Evaluation of an Anti-inflammatory Diet in Autoimmune and Metabolic Diseases
Conditions: Type1 Diabetes; Obesity Interventions: Dietary Supplement: Microbiome-targeted diet; Dietary Supplement: Usual care diet Sponsor: IRCCS San Raffaele Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2023 Category: Research Source Type: clinical trials
PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V)
DiscussionDespite the introduction of vaccination, there remains a need for pre-exposure prophylactic agents against SARS-CoV-2. Several patient groups are more vulnerable to COVID-19 disease by virtue of underlying health conditions, treatments received or suboptimal responses to vaccination.Trial registrationClinicalTrials.gov NCT04870333. EudraCT 2020-004144-28 (Source: Trials)
Source: Trials - March 13, 2023 Category: Research Source Type: clinical trials
An Open-label Study of ALPN-303 in Subjects With Autoimmune Cytopenias
Conditions: Immune Thrombocytopenia; Idiopathic Thrombocytopenic Purpura; Warm Autoimmune Hemolytic Anemia; Cold Agglutinin Disease Intervention: Drug: povetacicept Sponsor: Alpine Immune Sciences, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2023 Category: Research Source Type: clinical trials
